Aurinia Pharmaceuticals Inc.
GPTKB entity
Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Peter_Greenleaf
|
| gptkbp:country |
gptkb:Canada
|
| gptkbp:focus |
nephrology
autoimmune diseases |
| gptkbp:foundedYear |
1993
|
| gptkbp:headquartersLocation |
gptkb:Victoria,_British_Columbia,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aurinia Pharmaceuticals Inc.
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableApproval |
FDA approval for Lupkynis (2021)
|
| gptkbp:numberOfEmployees |
~200 (2023)
|
| gptkbp:product |
gptkb:Lupkynis
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:AUPH
|
| gptkbp:therapeuticArea |
lupus nephritis
|
| gptkbp:website |
https://www.auriniapharma.com/
|
| gptkbp:bfsParent |
gptkb:NASDAQ:AUPH
gptkb:TSX:AUP |
| gptkbp:bfsLayer |
8
|